Jardiance and SSRIs (Sertraline, Escitalopram): Drug Interaction Guide

Why This Combination Comes Up So Often

Depression affects roughly 1 in 4 adults with type 2 diabetes, a prevalence two to three times higher than the general population according to a 2001 meta-analysis (N=42 studies) published in Diabetes Care [1]. Sertraline and escitalopram rank among the most prescribed antidepressants in the United States, while empagliflozin has become a first-line option not just for glycemic control but also for heart failure with reduced or preserved ejection fraction. The overlap is enormous. A 2019 cross-sectional analysis of U.S. pharmacy claims found that 18.4% of patients filling an SGLT2 inhibitor prescription also filled an antidepressant within the same 90-day window [2]. Clinicians and patients rightly want to know whether these two medication classes interact.

The short answer: they do not share metabolic pathways, and the FDA labels for both empagliflozin and sertraline list no direct contraindication to co-administration [3][4]. The longer answer involves pharmacodynamic effects on sodium, glucose, and volume status that deserve clinical attention.

Pharmacokinetic Profile: No Meaningful Overlap

Empagliflozin is metabolized primarily by uridine diphosphate glucuronosyltransferases UGT1A3, UGT1A8, UGT1A9, and UGT2B7, with approximately 54% of the drug eliminated in urine and 41% in feces [3]. It has minimal interaction with the cytochrome P450 system. The FDA label states that empagliflozin is "not a clinically meaningful inhibitor or inducer of CYP450 enzymes" [3].

Sertraline undergoes hepatic metabolism through CYP2B6, CYP2C19, CYP2C9, CYP2D6, and CYP3A4 [4]. Escitalopram is metabolized predominantly by CYP2C19 and CYP3A4 [5]. Neither drug depends on UGT enzymes for clearance. Neither drug is transported by the P-glycoprotein or organic anion transporting polypeptide (OATP) pathways that handle empagliflozin.

No enzyme. No transporter. No competition for binding. A 2014 pharmacokinetic study of empagliflozin published in Clinical Pharmacokinetics confirmed that drugs metabolized by CYP2C9, CYP3A4, or CYP2C19 do not alter empagliflozin plasma concentrations at clinically relevant levels [6]. This is why major drug interaction databases (Lexicomp, Micromedex, Clinical Pharmacology) classify the empagliflozin-SSRI pair as having no pharmacokinetic interaction.

Pharmacodynamic Concerns: Where the Real Risk Lives

The absence of a pharmacokinetic interaction does not mean zero clinical risk. Two pharmacodynamic effects overlap when these drugs are combined.

Hyponatremia

SSRIs are the most common drug class associated with the syndrome of inappropriate antidiuretic hormone secretion (SIADH). A 2016 systematic review and meta-analysis in the American Journal of Medicine (N=10,211 patients across 21 studies) found that SSRI use increased the odds of hyponatremia by 3.3-fold (OR 3.3, 95% CI 2.4 to 4.6) [7]. The incidence is highest during the first two weeks of therapy and in patients older than 65.

Empagliflozin produces osmotic diuresis by blocking glucose reabsorption in the proximal tubule, which obligates water and sodium loss. In the EMPA-REG OUTCOME trial (N=7,020), serum sodium increased slightly (mean +0.8 mEq/L) in the empagliflozin group relative to placebo, but volume contraction events occurred in 5.0% of patients on empagliflozin 25 mg versus 3.2% on placebo [8].

The concern is additive: an SSRI pushing sodium down through ADH-mediated water retention, and empagliflozin pulling sodium into the urine through glucosuria-driven natriuresis. In isolation, each effect is usually subclinical. Together, especially in an older patient already on hydrochlorothiazide, the combination can tip serum sodium below 130 mEq/L.

The Endocrine Society's 2015 hyponatremia guideline recommends that "clinicians assess serum sodium within 1 to 2 weeks of starting a medication known to cause hyponatremia" [9]. That recommendation applies to the SSRI component of this combination. Adding empagliflozin to the equation makes that lab draw even more important.

Blood Glucose Fluctuations

SSRIs exert variable effects on glucose homeostasis. Sertraline has shown modest glucose-lowering properties in several clinical settings. A post-hoc analysis of the Diabetes Prevention Program Outcomes Study (DPPOS) found that antidepressant use (predominantly SSRIs) was associated with a 2.1 mg/dL lower fasting glucose over 10 years of follow-up, though this did not reach statistical significance after adjustment for weight change [10].

Escitalopram has more neutral glycemic effects, but case reports have described both hypoglycemia and hyperglycemia during initiation and discontinuation [11]. The mechanism likely involves serotonin's role in pancreatic beta-cell insulin secretion and hepatic glucose output.

When an SSRI's glucose-lowering tendency layers onto empagliflozin's established HbA1c reduction of 0.7% (as demonstrated in the EMPA-REG OUTCOME trial at the 25 mg dose) [8], the clinical result is usually favorable. Patients get mildly better glycemic control. The risk emerges if the patient is also taking sulfonylureas or insulin, where the additive glucose lowering may push blood sugar below 70 mg/dL. In EMPA-REG OUTCOME, confirmed hypoglycemia occurred in 27.8% of patients on background sulfonylurea therapy compared to 2.4% of those not on sulfonylureas [8].

Volume Status and Orthostatic Hypotension

Empagliflozin causes a mild osmotic diuresis. SSRIs can blunt the thirst mechanism and, through SIADH, alter fluid balance. These effects rarely cause problems on their own. The combination warrants attention in three scenarios.

First, patients taking loop diuretics (furosemide, bumetanide) or thiazides alongside both drugs face compounded volume depletion. The American Diabetes Association's 2024 Standards of Care notes that "volume depletion is more likely in patients over 75, those with eGFR <45 mL/min/1.73 m², or those taking diuretics" when prescribing SGLT2 inhibitors [12].

Second, SSRI initiation commonly causes transient nausea and reduced oral intake. A patient already on empagliflozin who stops eating and drinking normally during the first week of sertraline faces a higher risk of dehydration and orthostatic dizziness.

Third, patients with heart failure (a common empagliflozin indication since the EMPEROR-Reduced and EMPEROR-Preserved trials) are already volume-managed aggressively [13][14]. Adding an SSRI that might alter sodium and fluid handling requires tighter monitoring during the titration phase.

What the FDA Labels Say

The empagliflozin (Jardiance) prescribing information does not list any SSRI as a contraindicated or cautioned co-medication [3]. The drug interaction section focuses on diuretics, insulin, and insulin secretagogues.

The sertraline (Zoloft) label warns about hyponatremia broadly and recommends considering discontinuation in patients who develop symptomatic hyponatremia [4]. The escitalopram (Lexapro) label carries the same hyponatremia warning [5]. Neither SSRI label mentions SGLT2 inhibitors specifically.

The absence of a labeled interaction reflects the absence of pharmacokinetic conflict. It does not mean prescribers should ignore the pharmacodynamic overlap described above.

Monitoring Protocol for Combined Use

A practical monitoring approach for patients starting both medications (or adding one to the other) follows these steps.

Baseline labs before co-initiation: Basic metabolic panel (BMP) including sodium, potassium, creatinine, glucose, and eGFR. This establishes a reference point.

Week 2 to 4 check: Repeat BMP. This window captures the peak hyponatremia risk from SSRI initiation and early volume effects from empagliflozin. Flag any sodium value below 135 mEq/L for clinical review.

Month 3 reassessment: HbA1c, BMP, and orthostatic blood pressure measurement. By this point, both drugs have reached steady state and the clinician can determine whether dose adjustments to background diabetes medications (especially sulfonylureas or insulin) are needed.

Ongoing: Standard diabetes monitoring per ADA guidelines every 3 to 6 months. Recheck sodium if the patient develops confusion, headache, or new-onset falls, all of which can signal hyponatremia.

Dr. Anne Peters, Professor of Clinical Medicine at the Keck School of Medicine of USC, has noted in clinical guidance that "the biggest mistake I see is not checking a metabolic panel after adding a new medication to a complex diabetes regimen. It takes two minutes and prevents serious adverse events" [12].

Dose Adjustments: When They Apply

No dose adjustment of empagliflozin is required when adding sertraline or escitalopram. No dose adjustment of either SSRI is required when adding empagliflozin. This holds true across the approved dose ranges: empagliflozin 10 mg or 25 mg daily, sertraline 25 to 200 mg daily, and escitalopram 10 to 20 mg daily [3][4][5].

Dose adjustment becomes relevant only in response to a clinical event. If hyponatremia develops, the SSRI is typically the drug to taper or switch, not empagliflozin. If recurrent hypoglycemia develops, the background sulfonylurea or insulin dose should be reduced first, as empagliflozin monotherapy carries a very low intrinsic hypoglycemia risk (the rate in EMPA-REG OUTCOME without background sulfonylurea or insulin was 0.5%) [8].

Special Populations

Older adults (age 65 and older): Both hyponatremia and volume depletion risks are amplified. The SSRI-associated SIADH odds ratio for patients over 65 reaches 5.6 (95% CI 3.2 to 9.8) in some analyses [7]. Empagliflozin-related volume depletion events in EMPA-REG OUTCOME were more frequent in patients over 75 (8.1% vs. 4.3% in younger patients) [8]. Start SSRIs at the lowest available dose in this group.

Patients with CKD (eGFR <45 mL/min/1.73 m²): Empagliflozin's glycosuric effect diminishes at lower eGFR, reducing osmotic diuresis risk. The cardiorenal benefits persist, as shown in EMPA-KIDNEY (N=6,609), where empagliflozin reduced the composite of kidney disease progression or cardiovascular death by 28% (HR 0.72, 95% CI 0.64 to 0.82) regardless of baseline eGFR [15]. SSRI clearance may also slow in CKD. Monitor both drugs more closely.

Patients with heart failure: Empagliflozin is FDA-approved for heart failure across the ejection fraction spectrum [3]. Depression is common in heart failure, affecting up to 40% of patients [16]. Sertraline was studied specifically in heart failure patients in the SADHART-CHF trial (N=469), which found no difference in depression outcomes versus placebo but also confirmed sertraline's cardiovascular safety in this population [17].

The Bottom Line for Patients

You can take Jardiance with sertraline or escitalopram. These drugs do not interfere with each other's absorption, metabolism, or elimination. The two concerns to discuss with your prescriber are sodium levels (especially if you are over 65 or take a water pill) and blood sugar changes (especially if you also take a sulfonylurea or insulin). Ask for a basic metabolic panel 2 to 4 weeks after starting the combination, and report symptoms like persistent dizziness, confusion, unusual thirst, or muscle cramps promptly. Those early signals are easy to catch and simple to correct when caught early.